about
Endothelial-binding, proinflammatory T cells identified by MCAM (CD146) expression: Characterization and role in human autoimmune diseasesNew targets in psoriatic arthritisCirculating concentrations of interleukin (IL)-17 in patients with multiple sclerosis: Evaluation of the effects of gender, treatment, disease patterns and IL-23 receptor gene polymorphismsGene Expression Profiling in Peripheral Blood Cells and Synovial Membranes of Patients with Psoriatic ArthritisThe Assessment of Selected Bone and Cartilage Biomarkers in Psoriatic Patients from Poland.Psoriatic arthritis: an evolving matter.The immunogenetics of Psoriasis: A comprehensive review.The role of IL-17 in vitiligo: A reviewTherapeutic Effects of Erythroid Differentiation Regulator 1 on Imiquimod-Induced Psoriasis-Like Skin Inflammation.New treatments for inflammatory rheumatic disease.Emerging drugs for the treatment of axial and peripheral spondyloarthritis.The Role of T Helper 17 Cells and Other IL-17-Producing Cells in Bone Resorption and Remodeling.The IL-23-IL-17 axis in inflammatory arthritis.Emerging biomarkers in psoriatic arthritis.STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.The role of IL 23 in the treatment of psoriasis.Altered Immune Activation and IL-23 Signaling in Response to Candida albicans in Autoimmune Polyendocrine Syndrome Type 1IL-23 and Th17 Disease in Inflammatory ArthritisAutoimmunity in 2014.Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.CD4 T-Cell Dysregulation in Psoriatic Arthritis Reveals a Regulatory Role for IL-22.Targeting IL-17 in psoriatic arthritis.Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities.Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics.TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin.Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis.Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis.Psoriatic arthritis.Psoriatic Arthritis and Nail Psoriasis in a Patient with Concomitant Atopic Dermatitis.A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4+ or CD8+ T Cells Using Immunodeficient NOG Mice.T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities.
P2860
Q26991693-559A57F7-B356-419E-B52B-1029D59D95ADQ28069592-C1B090BD-D3A0-43EC-B09C-829A36E5C868Q33896806-BC011796-98EE-4067-9217-C461B26D8746Q35667354-EBB74831-72B8-4538-B333-2243D97B64F3Q35753415-A7D1747F-2AE7-4D38-8AE9-26B16C0D0024Q36182379-E9DB3BE4-4B0D-4D23-813E-5284F4AF3221Q36236780-58CDAD4A-CF7B-4ED2-91A9-18FCF7A8B9CCQ36625953-D2711328-6B51-47C8-81DE-060B525D88BBQ36667189-80B0F1C4-7640-4410-9FC0-A877363CA181Q38266252-35922A82-37DD-47EC-8D65-57A515AE42EAQ38313266-86F9EE0A-3FBF-4667-A9C9-1D9EBF0ED5D5Q38379550-344126BF-D7F6-4837-91A8-94B38967BEB5Q38439641-88BD8DEE-3949-4942-A208-99BA700180D6Q38646234-950E77BA-028C-4A68-84B8-EB6FCD7F127DQ38731119-DC116AC2-0BF2-499C-AE08-649F6F563DA5Q38969036-0A665DFF-1EF7-40ED-9CAB-B561DEDFB2FDQ38976762-1495473E-90CC-4EA4-B45E-1F3341826C32Q41619568-9E58F831-E8D5-4EA5-95E0-4800791BE0ABQ41674783-63C9722E-3485-4C92-A833-501F310B2F77Q42643483-232A1352-AAB0-42CB-85E4-EF0874D6C882Q43727420-8B5A2D28-0AA3-4476-BCBD-AE1B287F8BADQ45795234-8A337063-DB70-4AC2-81A3-01D152B4852FQ47140713-F36E037A-38AE-46F3-BEA6-119988B42FD9Q47696280-5A10B3B5-7E20-42AB-8943-444371C79805Q47704613-A868FD7B-FBDD-42E7-A17F-45D98BA88A98Q48296840-AE8C39F9-28E8-453A-B00F-2946E88A3D0EQ48362769-B5BC5DF0-526F-4F3D-B94D-B4800E9AF5FFQ49824739-09DCCA56-48B0-4D95-8B4C-1A5F82D351F4Q50034719-8C4C5A18-1F78-44F3-B50B-FFBFC54F42C6Q51656945-5E97B6EF-C6D6-47A5-8421-2321BDF32353Q52579030-B594E927-D3E7-40A7-BE92-09EFF11F573AQ52959192-289693D1-0950-4232-B6C4-0B0988AA7AE0Q55512008-ECEE2DE4-2F2D-46F4-B595-2906E2C17BD8
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The IL-23/IL-17 axis in psoriatic arthritis.
@en
The IL-23/IL-17 axis in psoriatic arthritis.
@nl
type
label
The IL-23/IL-17 axis in psoriatic arthritis.
@en
The IL-23/IL-17 axis in psoriatic arthritis.
@nl
prefLabel
The IL-23/IL-17 axis in psoriatic arthritis.
@en
The IL-23/IL-17 axis in psoriatic arthritis.
@nl
P2093
P2860
P1433
P1476
The IL-23/IL-17 axis in psoriatic arthritis.
@en
P2093
Elizabeth D Mellins
Erika Suzuki
Frank O Nestle
Iannis E Adamopoulos
P2860
P304
P356
10.1016/J.AUTREV.2014.01.050
P577
2014-01-11T00:00:00Z